Northern Trust Corp Acquires Shares of 436,062 MDxHealth SA (NASDAQ:MDXH)

Northern Trust Corp bought a new stake in shares of MDxHealth SA (NASDAQ:MDXH - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 436,062 shares of the company's stock, valued at approximately $1,033,000. Northern Trust Corp owned about 0.92% of MDxHealth at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MDXH. Geode Capital Management LLC bought a new stake in MDxHealth during the fourth quarter valued at approximately $25,000. Oppenheimer & Co. Inc. lifted its holdings in shares of MDxHealth by 100.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock worth $47,000 after acquiring an additional 10,000 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of MDxHealth in the 4th quarter worth approximately $63,000. Northern Right Capital Management L.P. bought a new stake in shares of MDxHealth in the 4th quarter worth approximately $246,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of MDxHealth by 715.2% in the 4th quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after acquiring an additional 108,000 shares during the last quarter.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a report on Saturday, May 24th.

MDxHealth Trading Up 4.3%

Shares of MDXH traded up $0.09 during mid-day trading on Monday, reaching $2.20. The company's stock had a trading volume of 74,687 shares, compared to its average volume of 87,074. The company's fifty day moving average price is $1.74 and its two-hundred day moving average price is $1.86. MDxHealth SA has a 52 week low of $1.35 and a 52 week high of $3.50. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The stock has a market cap of $104.03 million, a PE ratio of -1.45 and a beta of 1.32.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The firm had revenue of $24.29 million for the quarter, compared to analysts' expectations of $22.62 million. On average, analysts predict that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.